Pharmacosmos sees big potential in million-dollar acquisition

Family-owned Pharmacosmos wants to grow, which is why the company has paid up to USD 225m for US-based Abfero Pharmaceuticals last week, also acquiring its lead candidate SP-420 that Pharmacosmos says has a promising future ahead.
Photo: Pharmacosmos / PR
Photo: Pharmacosmos / PR
by ANDREAS LØNSTRUP, translated by daniel pedersen

Pharmacosmos took out the the big checkbook last week, when the family-owned company, which is based in Denmark, acquired the privately owned Boston-based business Abfero Pharmaceuticals.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading